about
Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary historyRNAi-mediated knock-down of arylamine N-acetyltransferase-1 expression induces E-cadherin up-regulation and cell-cell contact growth inhibitionExpression, purification, characterization and structure of Pseudomonas aeruginosa arylamine N-acetyltransferaseRapid birth-and-death evolution of the xenobiotic metabolizing NAT gene family in vertebrates with evidence of adaptive selectionStructural analysis of the genes for human arylamine N-acetyltransferases and characterisation of alternative transcripts.N-acetyltransferase 2 (NAT2) gene polymorphisms in Parkinson's disease.Polymorphisms of selected xenobiotic genes contribute to the development of papillary thyroid cancer susceptibility in Middle Eastern populationProbing the catalytic potential of the hamster arylamine N-acetyltransferase 2 catalytic triad by site-directed mutagenesis of the proximal conserved residue, Tyr190.A simple, bead-based approach for multi-SNP molecular haplotypingN-acetyltransferase 2 (NAT2) gene polymorphisms in colon and lung cancer patientsNAT2 gene polymorphisms in three indigenous groups in the Colombian Caribbean Coast regionN-acetyltransferase genotypes and the pharmacokinetics and tolerability of para-aminosalicylic acid in patients with drug-resistant pulmonary tuberculosis.Variation in NAT2 acetylation phenotypes is associated with differences in food-producing subsistence modes and ecoregions in Africa.Identification of N-acetyltransferase 2 (NAT2) transcription start sites and quantitation of NAT2-specific mRNA in human tissues.Association of NAT2 phenotype with risk of head and neck carcinoma: A meta-analysis.Arylamine N-acetyltransferases: what we learn from genes and genomes.Pharmacogenetics and anesthesiologists.Translating genomic biomarkers into clinically useful diagnostics.Structure/function evaluations of single nucleotide polymorphisms in human N-acetyltransferase 2Functional effects of single nucleotide polymorphisms in the coding region of human N-acetyltransferase 1.PhRMA white paper on ADME pharmacogenomics.Update on the pharmacogenetics of NATs: structural considerations.Part 3: Pharmacogenetic variability in phase II anticancer drug metabolism.Arylamine N-acetyltransferases: a structural perspective.Structure and transcriptional regulation of the Nat2 gene encoding for the drug-metabolizing enzyme arylamine N-acetyltransferase type 2 in mice.Possible association of NAT2 polymorphism with laryngeal cancer risk: an evidence-based meta-analysis.A long-lived luminescent probe to sensitively detect arylamine N-acetyltransferase (NAT) activity of cells.E. coli nitroreductase/CB1954 gene-directed enzyme prodrug therapy: role of arylamine N-acetlytransferase 2.Discordance between N-acetyltransferase 2 phenotype and genotype in a population of Hmong subjects.N-acetyltransferase 1 and 2 polymorphisms and risk of diabetes mellitus type 2 in a Saudi population.Genomic organization of human arylamine N-acetyltransferase Type I reveals alternative promoters that generate different 5'-UTR splice variants with altered translational activitiesProteasomal degradation of N-acetyltransferase 1 is prevented by acetylation of the active site cysteine: a mechanism for the slow acetylator phenotype and substrate-dependent down-regulation.Identification of a minimal promoter sequence for the human N-acetyltransferase Type I gene that binds AP-1 (activator protein 1) and YY-1 (Yin and Yang 1).NAT2 gene polymorphism: covert drug interaction causing phenytoin toxicity.Association between polymorphisms at N-acetyltransferase 1 (NAT1) & risk of oral leukoplakia & cancer.GSTT1, GSTM1, GSTM3 and NAT2 polymorphisms in laryngeal squamous cell carcinoma in a Greek population.Redox regulation of the human xenobiotic metabolizing enzyme arylamine N-acetyltransferase 1 (NAT1). Reversible inactivation by hydrogen peroxide.Peroxynitrite irreversibly inactivates the human xenobiotic-metabolizing enzyme arylamine N-acetyltransferase 1 (NAT1) in human breast cancer cells: a cellular and mechanistic study.Study of NAT2 gene polymorphisms in an Indian population: association with plasma isoniazid concentration in a cohort of tuberculosis patients.NAT2 sequence polymorphisms and acetylation profiles in Indians.
P2860
Q21283781-C288FFBA-963C-48EA-81E8-F1EB5D27B93AQ28477123-FB412AB1-9204-4B3D-843D-9E5028E2206BQ28493134-D7D64332-7BBA-41F1-8E3E-5C7896E4D878Q28709654-24829B18-E762-4027-B72F-48E6E0B582B0Q31163532-B7143DC3-1ED7-4E4F-945E-6487519A4FFDQ33237936-71D806F2-7BA2-424B-A1B0-314EBD66A765Q33349220-AF6BF4E2-405B-4FAE-8355-E1D0477F3973Q33587691-1D32C179-C475-402A-B8C6-001F917022FFQ33754849-4B0DD264-C847-4F1A-9FB7-4C4E4FFE4AB1Q34944536-90C0376B-9A1B-45E6-85F7-4B10E21403B1Q35149733-A79E322B-922E-4B94-881C-03BA9302A7F3Q35746163-AE9C0233-6E97-432F-A0BC-8ED152581FF3Q35856283-04FB9215-1089-4918-B149-53235114F6C6Q35911107-1E314F92-F680-4ED0-8E06-005C47C6BFA8Q35995433-398AB058-3027-40F8-8EEC-D5DA0B470C4EQ36300809-C572A7E5-0FC7-4352-A216-033AF434BD68Q36317007-EFDA4954-2F28-407B-87E0-356E617BDD7BQ36411676-E53B539A-D927-4E78-B349-62E909B6C6C8Q36828813-7BBDB868-F4E7-4786-9C75-1A2CBE8ED3C2Q36953746-9C1757AF-D68E-405F-91BB-37C30E3DD9D4Q37182212-C2F8444E-A327-4BE4-B97F-6AA89D8425C3Q37329162-C9BB1DA3-D4D4-4B7B-9E9F-28B489F74726Q37887337-DCD244F2-2A85-483B-87DE-7EC24CDC4334Q38091708-49B22FCD-E664-4837-93F7-5756BF609F5BQ38351718-A15F8937-5C1C-428C-A5FB-F3ACE9E6F9B4Q38421437-36E2669C-3184-4614-9CA1-506690E37BF8Q39410980-8F477A8A-08D5-4A41-A5A9-394FDD11585EQ39965327-67AC32AD-374D-4C38-9815-B1C70EACB181Q40311100-DC7C6517-FCF9-41E1-8B1D-A3D6703AE185Q40497358-E49244E6-27E3-41B4-9F20-615F8772CB16Q40503646-17BDD506-8070-435E-8129-58EF0F550FB6Q40574663-42CD1161-B0B4-40DD-998B-E7A9F141DE9FQ40639399-1A1D000B-2DCF-4889-8017-7BE2FEB99D50Q41675062-93EC03DD-7870-441C-AB87-7D6B4F00BF61Q42393340-131CACBA-DB3C-4C9F-B3DF-38C64230368EQ43239477-9A000338-E339-493A-BFA9-9B927A9C39CDQ44495336-10EC66D0-3E81-482F-933E-F37831D8208CQ44691529-C6D50600-7AFD-445D-B977-A6A32317F844Q46058560-E11C4473-8549-4F52-BA9C-4E7F0BBEFA22Q46148230-2699AD68-3ACA-4739-A10C-9453A94CD2D2
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Pharmacogenetics of the arylamine N-acetyltransferases.
@ast
Pharmacogenetics of the arylamine N-acetyltransferases.
@en
Pharmacogenetics of the arylamine N-acetyltransferases.
@nl
type
label
Pharmacogenetics of the arylamine N-acetyltransferases.
@ast
Pharmacogenetics of the arylamine N-acetyltransferases.
@en
Pharmacogenetics of the arylamine N-acetyltransferases.
@nl
prefLabel
Pharmacogenetics of the arylamine N-acetyltransferases.
@ast
Pharmacogenetics of the arylamine N-acetyltransferases.
@en
Pharmacogenetics of the arylamine N-acetyltransferases.
@nl
P2093
P2860
P356
P1476
Pharmacogenetics of the arylamine N-acetyltransferases
@en
P2093
P2860
P2888
P356
10.1038/SJ.TPJ.6500053
P577
2002-01-01T00:00:00Z
P5875
P6179
1043593908